Clinical Trial Finder

Inclusion Criteria:

1. Age ≥ 18 years. 2. Histologically or cytologically proven metastatic skin melanoma. 3. Melanoma must be at one of the following AJCC 2009 stages:

• - Unresectable (or residual) regional metastatic melanoma, i.e. in terms of AJCC 2009 classification unresectable stage III melanoma, or.

• - Stage IV melanoma, i.e. distant metastatic disease (any T, any N, M1a, M1b or M1c), and normal LDH.

• - Patients have failed on standard treatment options.

4. Patients with brain metastases have to be neurologically stable for at least 2 months and should not use dexamethasone. 5. Presence of measurable progressive disease according to RECIST version 1.1. 6. Expected survival of at least 3 months. 7. WHO performance status ≤1. 8. Within the last 2 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which should be within the ranges specified: Lab Parameter Range Hemoglobin ≥ 6,0 mmol/l Granulocytes ≥ 1,500/µl Lymphocytes ≥ 700/µl Platelets ≥ 100,000/µl Creatinine clearance ≥ 60 min/ml Serum bilirubin ≤ 40 µmol/l ASAT and ALAT ≤ 5 x the normal upper limit LDH ≤ 2 x the normal upper limit. 9. Viral tests must be performed at least 30 days before surgery:

• - Negative for HIV type 1/2, HTLV and TPHA.

• - No HBV (hepatitis B virus) antigen or antibodies against HBc in the serum.

• - No antibodies against HCV (hepatitis C virus) in the serum.

10. Able and willing to give valid written informed consent. 11. Progressive disease on prior treatment with f.e. BRAF-inhibitors, MEK-inhibitors or immunotherapy, including anti-PD1 treatment. Systemic therapy must have been discontinued for at least four weeks before start of study treatment.

Exclusion Criteria:

1. Patients with brain metastases who are neurologically unstable and/or use dexamethasone. 2. Clinically significant heart disease (NYHA Class III or IV) 3. Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study. 4. Active immunodeficiency disease, autoimmune disease requiring immune suppressive drugs or autoimmune adverse events following treatment with checkpoint inhibitors. Vitiligo is not an exclusion criterion. 5. Subjects with a condition requiring systemic chronic steroid therapy (≥ 10mg/day prednisone or equivalent) or any immunosuppressive therapy within 14 days prior to planned date for first dose of study treatment. Topical, inhaled, nasal and ophthalmic steroids, and adrenal replacement therapy are allowed. 6. Other malignancy within 2 years prior to entry into the study, except for treated non-melanoma skin cancer and in situ cervical carcinoma. 7. Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study. 8. Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the associated with the participation, study drug administration, or would impair the ability of the patient to receive protocol therapy. 9. Lack of availability for follow-up assessments. 10. Pregnancy or breastfeeding. 11. Known allergy to penicillin or streptomycin (used during the culturing of T cells)

The ACTME is an investigator initiated, single center phase I/II clinical trial for patients with progressive unresectable stage III or stage IV melanoma. Patients are conditioned by low-dose IFN-alpha and treated with ACT and PD-1 antibodies. With this approach the investigators hope to solve 4 of the most important aspects curtailing the efficacy of current immunotherapies in metastatic melanoma: 1. the lack of sufficient numbers of activated tumor-reactive T cells in patients by providing ACT; and. 2. the inhibition of T-cell effector function through PD-1 signalling by administration of nivolumab; as well as. 3. the toxicity of high-dose IL-2, and. 4. long term hospitalization of patients due to the conditioning-regimen used in most ACT protocols by replacing it with low-dose IFN-alpha treatment. The trial consists of both a phase I part to determine safety and feasibility and a phase II part to evaluate first clinical activity of IFN-alpha, nivolumab and TIL. The treatment with IFN-alpha will be added after the combination of TIL and nivolumab has proven to be safe in the first cohort of the phase I part of the trial.

Arms

Experimental: Treatment with nivolumab plus TIL

In the first cohort the subcutaneous IFN-alpha injections will be omitted and the combination of nivolumab and TIL is given. Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion TILs are given at a dose ranging between 2.5-7.5x10^8 T cells i.v. once every three weeks, three times per cycle.

Experimental: Treatment with Nivolumab plus TIL and IFN-alpha

In the second cohort of the first phase and the second phase of the trial patients will be treated with subcutaneous IFN-alpha injections in combination with TIL and nivolumab. IFN-alpha is given at a fixed dose of 3 million IU s.c. every day, for 11 weeks, starting one week before the first TIL infusion Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion TILs are given at a dose ranging between 2.5-7.5x10^8 T cells i.v. once every three weeks, three times per cycle.

Interventions

Drug: - Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha

During 15 weeks patients will be treated with nivolumab (3mg/kg i.v.) once every two weeks. Four weeks after starting nivolumab, patients will receive their first TIL infusion (2.5-7.5x10^8 T cells i.v.) once every three weeks for three infusions. In the second group treatment with IFN-alpha (3 million IU s.c.) daily will be added one week before the first TIL infusion and will be continued for 11 weeks.